Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection.
Khachi
H
H
O'Connell
R
R
Ladenheim
D
D
Orkin
C
C
D000328:Adult; D019380:Anti-HIV Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D061466:Lopinavir; D008297:Male; D011744:Pyrimidinones / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D017828:Rifabutin / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D019438:Ritonavir / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D044967:Serum / Q000737:chemistry; D014376:Tuberculosis / Q000188:drug therapy*; D055815:Young Adult
D019380:Anti-HIV Agents; D000995:Antitubercular Agents; D011744:Pyrimidinones; D017828:Rifabutin; D061466:Lopinavir; D019438:Ritonavir